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community of this avoidable antituberculosis-related hepatotoxicity.
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Hepatotoxicity is the main problem of antituberculotic treatment like isoniazid, rifampicin and pyrazinamide. We evaluate the outcomes of re-challenge for anti-
tuberculosis drug in order to manage hepatotoxicity due to antituberculotic therapy in a patient with cerebral tuberculosis. A female patient
was diagnosed with cerebral tuberculosis and had been treated with 5 regimens of antituberculotic drug: isoniazid, rifampicin, pirazinamid, ethambutol, and
streptomycin. After four days, the patient felt several adverse reactions such as abdominal discomfort, nausea, and vomiting. Following this, a liver function test
was performed. The levels of SGOT and SGPT elevated 15 times higher cted on day than the normal upper limit, which also indicated antituberculotic drug
induced hepatotoxicity. A sequential rechallenge method was performed to overcome this problem. The method was successful to manage hepatotoxicity induced
by antituberculotic therapy.
Hepatotoxicity is the main problem of antituberculosis treatment
like isoniazid, rifampicin and pyrazinamide because it can seriously
contribute to nonadherence, eventually contributing to treatment
failure, relapse, or the emergence of drug resistance [1]. Anti-TB
drug–induced hepatotoxicity is associated with a mortality of 6%–
12% if these drugs are continued after the onset of symptoms [2].
There were several mechanism of antituberculosis that caused
hepatotoxicity. Interaction of rifampicin and isoniazid can induced
toxic metabolit of isoniazid that damage liver, and also the
interaction increase hydrazine-production that toxic to liver.
Pyrazinamide inhibit CYP450 and nicotinamide adenine
dinucleotide [3]. According to American Thoracic Society the
patients who experienced hepatotocity induced by antituberculosis
can be given rechallenge methods to overcome it [4]. In Indonesia,
antituberculosis hepatotoxicity often occurs but is not well
documented. The aim of this study was to evaluate the outcomes
of rechallenge for anti-tuberculosis drug in order to manage
hepatotoxicity due to antituberculosis therapy in a patient with
cerebral tuberculosis.
This was a case report. Hospital X approved this study. Informed
consent was obtained from the patient
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A female patient (age: 45, weight: 45 kg, height : 145 cm)
was diagnosed with cerebral tuberculosis and had been
treated with 5 regimens of antituberculosis drug: isoniazid
225 mg(H), rifampicin 450 mg(R), pyrazinamide 1200
mg(Z), ethambutol 825 mg(E), and streptomycin injection
1000 mg(S). The initial laboratory test for SGOT and
SGPT performed on the patient prior to the administration
of antituberculosis drug was normal (SGOT 33.6 U/L and
SGPT 32.5 U/L). After four days, the patient felt several
adverse reactions such as abdominal discomfort, nausea,
and vomiting. Following this, a liver function test was
conducted on day 9. The levels of SGOT and SGPT
elevated to 596.7 U/L and 273.7 U/L respectively. These
were approximately 15 times higher than the normal
upper limit, which also indicated antituberculosis drug
induced hepatotoxicity.
A sequential rechallenge method was performed on day
9 by suspending isoniazid, rifampicin, and pyrazinamide. The
liver function test on day 12 still showed the increasing
levels of SGOT and SGPT (753.8 U/L and 877.1
U/L respectively), and therefore the administration
of ethambutol was discontinued. After evaluating for 9
days, another liver function test was performed on day
21. The SGOT and SGPT levels decreased to 27.7 U/L and
103.5 U/L respectively. In turn, ethambuthol was reinitiated
to the patient. On Day 24, the liver enzyme was within the
normal range of values: SGOT 25.6 U/L and SGPT 62.7 U/L.
Subsequently, on that day, isoniazid and rifampicin were
readministered to the patient. Finally, on day 56, the
laboratory test for SGOT and SGPT showed 55.4 U/L and
30.3 U/L respectively, pyranzinamid were readministered to
the patient accordingly.
There were some strategy to do rechallenge in patient tuberculosis but the
evidence was still little other that expert opinion to guide the re-introduction of TB
medications [5]. In this study the clinicians used sequential method by adding
one by one the anti-TB drug. When when hepatotoxic occurs first, the clinicians
stop the use of isoniazid, rifampicin and pyrazinamid due to high potential of
hepatotoxicity of these drug [6]. But after few days the SGOT and SGPT still
increase then the clinician stop the ethambutol. There was one evidence showed
ethambutol increase liver function test but the mechanism still unknown [7]. And
clinician still use streptomycin because it has no effect on hepatotoxicity [3].
When the liver function was normal the clinician first re-introduced ethambutol
then give isoniazid and rifampicin and the last one was pyrazinamid because it
was the most potential hepatotoxic [8]. The dose given in this rechallenge used
American thoracic society methods which given in full dose from the first day it
was re-introduce and from the study comparison of American thoracic society
with british thoracic society guideline showed no difference [9]. These sequential
was success showed by normal liver function test after the treatment.
Note :
Day 1: RHZES Day 9: ES Day 12: S
Day 21: ES Day 24: RHES Day 56: RHZES 
In this study, sequential rechallenge to manage hepatotoxicity induced by
antituberculosis therapy was successful. It should be carried out cautiously by
monitoring liver function test in patient receiving antituberculosis drug to prevent
morbidity and mortality
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